Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-338 in relapsed or refractory B-cell lymphoma
CTR20220641Phase 2Completed
- Sponsor
- Chongqing Fuchuang Pharmaceutical Research
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LOXO-338 in malignant B-cell neoplasm, mantle cell lymphoma (MCL), sponsored by Chongqing Fuchuang Pharmaceutical Research. Started Mar 2022; status: completed.
02
Drugs
LOXO-338
03
Conditions
malignant B-cell neoplasmmantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20220641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220641.